“HEPCVEL” (Sofosbuvir 400 mg and Velpatasvir 100 mg) this mix is used to treat the infection of chronic viral hepatitis C (HCV) of all six genotypes: 1, 2, 3, 4, 5, 6. Sofosbuvir and Velpatasvir is an effective formula of two active substances against the hepatitis C virus. This panthenotypic scheme reduces the amount of hepatitis C virus in the body by preventing its replication in the blood and tissues.
General information for medicine identification:
1.1. Trade (proprietary) name of the medicine: Hepcvel
1.2. International (non-proprietary) name: sofosbuvir and velpatasvir.
1.3. Dosage form and destination: film-coated tablets, for oral administration.
Active substances: active substances Hepcvel are sofosbuvir and velpatasvir. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
1.5. Pharmacotherapeutic group: antiviral.
Indications for use:
Hepcvel combined medicine with a fixed dose of sofosbuvir, nucleotide analog inhibiting the polymerase NS5B of HCV, and velpatasvir, a new inhibitor of NS5A. The medicine is intended for the treatment of chronic hepatitis C genotypes 1, 2, 3, 4, 5 and 6 in patients older than 18 years
- Without cirrhosis of the liver or with compensated cirrhosis of the liver;
- With decompensate liver cirrhosis with the combined use of ribavirin.
Do not take the medicine and tell the doctor immediately if; you have the allergy to Sofosbuvir and Velpatasvir or any other component of the medicine. A combined treatment regimen using velpatasvir, sofosbuvir and ribavirin contraindicated in patients who have contraindications to ribavirin.
Hepcvel Side effects are mild and occur in no more than 20% of patients. Of the most common can be: